The Cell Culture Revolution: Commercializing Therapeutic Cell Systems

In recent years, a growing number of observers have raised concerns about conflicts of interests in the growing psychedelics industry. Beginning with a discussion of cases that have

Characterizing MSI status in challenging samples, including those with ambiguous results or small shifts, can be difficult. Endometrial and other cancers tend to have fewer, smaller marker shifts making MSI analysis cumbersome.

Everyone makes the best extracts. But are they optimized? And what does “the best” mean; does it mean high yield, high quality, or both? And what is quality anyway? Quality begins in the cultivation process and continues throughout the handling of the product from seed to sale. At OutCo, we’ve studied our production pipeline and extraction methodologies to offer optimized products to our patients. Finding the ideal balance between yield and consumer rating, we were able to optimize extraction protocols for controlled mixtures of compounds. Our custom methods enable us to create products with designer cannabinoid and terpene ratios, customized to patients’ and doctors’ needs. All of this was achieved in an efficient manner through the use of design of experiment (DoE) techniques, and continuous improvement of all processes.

Collaborative approaches can help develop the quality and efficiency of the clinical microbiology laboratory with the goal of improving patient outcomes.